CN104395470B - 抗‑gcc抗体分子和其用于测试对gcc标靶治疗的易感性的用途 - Google Patents

抗‑gcc抗体分子和其用于测试对gcc标靶治疗的易感性的用途 Download PDF

Info

Publication number
CN104395470B
CN104395470B CN201380033309.4A CN201380033309A CN104395470B CN 104395470 B CN104395470 B CN 104395470B CN 201380033309 A CN201380033309 A CN 201380033309A CN 104395470 B CN104395470 B CN 104395470B
Authority
CN
China
Prior art keywords
gcc
antibody
antibody molecule
cancer
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201380033309.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN104395470A (zh
Inventor
海伦·艾利森·弗兰克
艾丽斯·A·麦克唐纳
特雷莎·L·奥基夫
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Millennium Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49477498&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN104395470(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Millennium Pharmaceuticals Inc filed Critical Millennium Pharmaceuticals Inc
Publication of CN104395470A publication Critical patent/CN104395470A/zh
Application granted granted Critical
Publication of CN104395470B publication Critical patent/CN104395470B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/988—Lyases (4.), e.g. aldolases, heparinase, enolases, fumarase

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychology (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
CN201380033309.4A 2012-04-27 2013-04-27 抗‑gcc抗体分子和其用于测试对gcc标靶治疗的易感性的用途 Active CN104395470B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261639376P 2012-04-27 2012-04-27
US61/639,376 2012-04-27
PCT/US2013/038542 WO2013163633A1 (en) 2012-04-27 2013-04-27 Anti-gcc antibody molecules and use of same to test for susceptibility to gcc-targeted therapy

Publications (2)

Publication Number Publication Date
CN104395470A CN104395470A (zh) 2015-03-04
CN104395470B true CN104395470B (zh) 2018-02-06

Family

ID=49477498

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380033309.4A Active CN104395470B (zh) 2012-04-27 2013-04-27 抗‑gcc抗体分子和其用于测试对gcc标靶治疗的易感性的用途

Country Status (41)

Country Link
US (3) US9000129B2 (enExample)
EP (1) EP2841575B1 (enExample)
JP (2) JP6472746B2 (enExample)
KR (1) KR102046435B1 (enExample)
CN (1) CN104395470B (enExample)
AR (1) AR090884A1 (enExample)
AU (1) AU2013251312B2 (enExample)
CA (1) CA2871614C (enExample)
CL (1) CL2014002911A1 (enExample)
CO (1) CO7280144A2 (enExample)
CR (1) CR20140497A (enExample)
CY (1) CY1122557T1 (enExample)
DK (1) DK2841575T3 (enExample)
DO (1) DOP2014000242A (enExample)
EA (1) EA034689B1 (enExample)
EC (1) ECSP14028523A (enExample)
ES (1) ES2749181T3 (enExample)
GE (1) GEP201706737B (enExample)
HR (1) HRP20191690T1 (enExample)
HU (1) HUE046404T2 (enExample)
IL (1) IL235307B (enExample)
LT (1) LT2841575T (enExample)
MA (1) MA37569B1 (enExample)
ME (1) ME03560B (enExample)
MX (1) MX362020B (enExample)
MY (1) MY188442A (enExample)
NZ (1) NZ701601A (enExample)
PE (1) PE20142322A1 (enExample)
PH (1) PH12014502399B1 (enExample)
PL (1) PL2841575T3 (enExample)
PT (1) PT2841575T (enExample)
RS (1) RS59370B1 (enExample)
SA (1) SA113340502B1 (enExample)
SG (1) SG11201406855TA (enExample)
SI (1) SI2841575T1 (enExample)
SM (1) SMT201900536T1 (enExample)
TN (1) TN2014000454A1 (enExample)
TW (1) TWI631137B (enExample)
UA (1) UA117910C2 (enExample)
WO (1) WO2013163633A1 (enExample)
ZA (1) ZA201407723B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025061149A1 (zh) * 2023-09-21 2025-03-27 南京传奇生物科技有限公司 抗gcc抗体、嵌合抗原受体及其用途

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3031851C (en) 2009-10-23 2020-07-07 Amgen British Columbia Anti-gcc antibody molecules and related compositions and methods
WO2015058301A1 (en) * 2013-10-21 2015-04-30 The Centre For Drug Research And Development Anti-podocalyxin antibodies and methods of using the same
CA2936907C (en) 2014-02-14 2022-06-07 Arkansas Children's Hospital Research Institute, Inc. Acetaminophen protein adducts and methods of use thereof
AU2015358373B2 (en) * 2014-12-03 2021-05-27 Arkansas Children's Research Institute Anti-acetaminophen antibodies and acetaminophen protein adducts
CN109311994B (zh) 2015-10-01 2022-06-07 药物研究及发展中心 抗足糖萼蛋白抗体及其使用方法
JP7356351B2 (ja) * 2016-12-12 2023-10-04 エクセラ・バイオサイエンシーズ・インコーポレイテッド マイクロキャピラリーアレイを使用したスクリーニングのための方法およびシステム
KR102080887B1 (ko) * 2017-11-07 2020-02-24 고려대학교 산학협력단 Gcc2 유전자 또는 단백질을 과발현하는 엑소좀 기반 폐암 진단 또는 예후 예측용 마커 조성물
US11568657B2 (en) 2017-12-06 2023-01-31 Ventana Medical Systems, Inc. Method of storing and retrieving digital pathology analysis results
WO2019110561A1 (en) * 2017-12-06 2019-06-13 Ventana Medical Systems, Inc. Method of storing and retrieving digital pathology analysis results
FI3846788T3 (fi) * 2018-09-05 2025-12-17 Univ Amsterdam Pde11-estäjiä parkinsonin taudin hoitoon
WO2021205325A1 (en) * 2020-04-08 2021-10-14 Pfizer Inc. Anti-gucy2c antibodies and uses thereof
IL296519A (en) * 2020-06-02 2022-11-01 Teijin Pharma Ltd Anti-igf-1 receptor humanized antibody
CN118146381A (zh) * 2020-12-17 2024-06-07 合肥梧桐生物科技有限公司 Gucy2c结合分子及其用途
WO2022216079A1 (ko) * 2021-04-07 2022-10-13 주식회사 엘지화학 Gucy2c 결합 폴리펩타이드 및 그의 용도
EP4594364A1 (en) * 2022-09-28 2025-08-06 Legend Biotech Ireland Limited Antibody and chimeric antigen receptors targeting gcc and methods of use thereof
AR130916A1 (es) 2022-11-01 2025-01-29 Heidelberg Pharma Res Gmbh Anticuerpo anti-gucy2c y usos del mismo
CN116535514B (zh) * 2023-06-15 2024-02-02 上海斯丹赛生物技术有限公司 抗鸟苷酸环化酶c抗体及其在癌症治疗中的应用
CN117069848B (zh) * 2023-08-02 2025-02-28 武汉爱博泰克生物科技有限公司 抗人cd146兔单克隆抗体及其应用
EP4566631A1 (en) 2023-12-06 2025-06-11 Heidelberg Pharma Research GmbH New antibody drug conjugate as well as methods of production and uses thereof
CN120965861A (zh) * 2025-10-22 2025-11-18 杭州博茵生物技术有限公司 一种Fc效应消除的新型骨架流式抗体及其制备方法与应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010065293A1 (en) * 2008-12-03 2010-06-10 Boehringer Ingelheim Pharmaceuticals Inc. Antibodies for guanylyl cyclase receptors
WO2011050242A1 (en) * 2009-10-23 2011-04-28 Millennium Pharmaceuticals, Inc. Anti-gcc antibody molecules and related compositions and methods

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5237051A (en) 1990-12-06 1993-08-17 Vanderbilt University Purified enterotoxin receptor protein
US5601990A (en) 1994-09-13 1997-02-11 Thomas Jefferson University Methods of diagnosing colorectal tumors and metastasis thereof
US5879656A (en) 1993-10-26 1999-03-09 Thomas Jefferson University Methods of treating metastatic colorectal cancer with ST receptor binding compounds
US5518888A (en) 1993-10-26 1996-05-21 Thomas Jefferson University ST receptor binding compounds and methods of using the same
US7097839B1 (en) 1993-10-26 2006-08-29 Thomas Jefferson University ST receptor binding compounds and methods of using the same
US6060037A (en) 1993-10-26 2000-05-09 Thomas Jefferson University Compositions that specifically bind to colorectal cancer cells and methods of using the same
US6455251B1 (en) 1994-09-13 2002-09-24 Thomas Jefferson University Methods of and kits and compositions for diagnosing colorectal tumors and metastasis thereof
CA2254082C (en) 1996-05-03 2012-09-11 Thomas Jefferson University Metastatic colorectal cancer vaccine
US6602659B1 (en) 1996-05-03 2003-08-05 Thomas Jefferson University Methods of and kits and compositions for diagnosing colorectal tumors and metastasis thereof
US6120995A (en) 1997-08-07 2000-09-19 Thomas Jefferson University Compositions that specifically bind to colorectal cancer cells and methods of using the same
US6696550B2 (en) 1998-07-23 2004-02-24 Millennium Pharmaceuticals, Inc. Humanized anti-CCR2 antibodies and methods of use therefor
US8092514B1 (en) 1998-11-16 2012-01-10 Boston Scientific Scimed, Inc. Stretchable anti-buckling coiled-sheet stent
US20040031072A1 (en) 1999-05-06 2004-02-12 La Rosa Thomas J. Soy nucleic acid molecules and other molecules associated with transcription plants and uses thereof for plant improvement
WO2001073133A1 (en) 2000-03-27 2001-10-04 Thomas Jefferson University Compositions and methods for identifying and targeting cancer cells
TWI255272B (en) 2000-12-06 2006-05-21 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
ES2372686T3 (es) 2001-01-26 2012-01-25 Inhibitex, Inc. Anitcuerpos monoclonales dirigidos contra la proteína clfa y modo de empleo en el tratamiento y prevención de infecciones.
JP4206272B2 (ja) 2001-03-29 2009-01-07 サイナージィ ファーマスーティカルズ、インコーポレイテッド 組織炎症及び発癌を治療するためのグアニル酸シクラーゼ受容体アゴニスト
NZ529494A (en) 2001-04-13 2005-08-26 Biogen Idec Inc Antibodies to VLA-1
WO2003057838A2 (en) 2001-12-28 2003-07-17 Abgenix, Inc. Antibodies against the muc18 antigen
US20040110933A1 (en) 2002-09-13 2004-06-10 Dyax Corporation CD44-binding ligands
DE10254601A1 (de) 2002-11-22 2004-06-03 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
US7371727B2 (en) 2003-01-28 2008-05-13 Microbia, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US7304036B2 (en) 2003-01-28 2007-12-04 Microbia, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US8206704B2 (en) 2003-02-10 2012-06-26 Thomas Jefferson University Use of GCC ligands
CA2525120C (en) 2003-05-14 2013-04-30 Domantis Limited A process for recovering polypeptides that unfold reversibly from a polypeptide repertoire
US7871610B2 (en) 2003-08-12 2011-01-18 Dyax Corp. Antibodies to Tie1 ectodomain
EP2722060A3 (en) 2004-06-25 2015-01-07 Thomas Jefferson University Guanylyl cyclase C ligands
US20080267971A1 (en) 2004-12-21 2008-10-30 Green Larry L Antibodies Directed to Angiopoietin-2 and Uses Thereof
AR056857A1 (es) 2005-12-30 2007-10-24 U3 Pharma Ag Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos
CN103601792B (zh) 2007-06-04 2016-06-29 协同医药品公司 有效用于胃肠功能紊乱、炎症、癌症和其他疾病治疗的鸟苷酸环化酶激动剂
PL2188306T3 (pl) * 2007-08-10 2017-01-31 Janssen Biotech, Inc. Fragmenty powstałe po cięciu immunoglobuliny jako wskaźniki choroby oraz kompozycje do ich wykrywania i wiązania
MY161564A (en) 2007-08-10 2017-04-28 Regeneron Pharma High affinity human antibodies to human nerve growth factor
RS51987B (sr) * 2007-11-30 2012-02-29 Genentech Inc. Vegf polimorphizmi i anti-angiogenezna terapija
CA2760050A1 (en) 2008-05-13 2009-11-19 Thomas Jefferson University Guanylyl cyclase c qrt-pcr
JP2011523662A (ja) 2008-06-04 2011-08-18 シナジー ファーマシューティカルズ インコーポレイテッド 胃腸障害、炎症、癌、およびその他の障害の治療のために有用なグアニル酸シクラーゼのアゴニスト
ES2624828T3 (es) 2008-07-16 2017-07-17 Synergy Pharmaceuticals Inc. Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros
PL2881402T3 (pl) * 2009-02-12 2017-10-31 Cell Signaling Technology Inc Ekspresja zmutowanej ROS w ludzkim raku wątroby
AU2010217160C1 (en) 2009-02-25 2015-07-02 Diagnocure Inc. Method for detecting metastasis of GI cancer
WO2010104035A1 (ja) * 2009-03-12 2010-09-16 学校法人近畿大学 非小細胞肺癌に対する化学療法の治療効果予測方法
CA2801729A1 (en) 2009-06-15 2010-12-23 Thomas Jefferson University Compositions for and methods of activating guanylyl cyclase c
US20120251509A1 (en) 2009-10-22 2012-10-04 Waldman Scott A Cell-based anti-cancer compositions and methods of making and using the same
US9169329B2 (en) * 2010-06-01 2015-10-27 Ludwig Institute For Cancer Research Antibodies directed to the receptor tyrosine kinase c-Met
KR20140003393A (ko) * 2010-08-13 2014-01-09 에프. 호프만-라 로슈 아게 베바시주맙 병용 치료법을 위한 바이오마커인 뉴로필린
US20150086481A1 (en) 2011-07-28 2015-03-26 Memorial Sloan-Kettering Cancer Center Diagnosis and treatment of parkinson's disease
US9156915B2 (en) 2012-04-26 2015-10-13 Thomas Jefferson University Anti-GCC antibody molecules
KR20150122730A (ko) * 2013-02-28 2015-11-02 밀레니엄 파머슈티컬스 인코퍼레이티드 암의 치료에서 항-gcc 항체-약물 콘주게이트 및 dna 손상 제제의 투여

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010065293A1 (en) * 2008-12-03 2010-06-10 Boehringer Ingelheim Pharmaceuticals Inc. Antibodies for guanylyl cyclase receptors
WO2011050242A1 (en) * 2009-10-23 2011-04-28 Millennium Pharmaceuticals, Inc. Anti-gcc antibody molecules and related compositions and methods

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Functional Inactivation of the Human Guanylyl Cyclase C Receptor:Modeling and Mutation of the Protein Kinase-like Domain;Rashna Bhandari et al.;《Biochemistry》;20010714;第40卷;第9196-9206 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025061149A1 (zh) * 2023-09-21 2025-03-27 南京传奇生物科技有限公司 抗gcc抗体、嵌合抗原受体及其用途

Also Published As

Publication number Publication date
ES2749181T3 (es) 2020-03-19
PL2841575T3 (pl) 2020-01-31
BR112014026742A2 (pt) 2017-07-11
US9273146B1 (en) 2016-03-01
ME03560B (me) 2020-07-20
MY188442A (en) 2021-12-09
TW201348258A (zh) 2013-12-01
US20130287783A1 (en) 2013-10-31
CL2014002911A1 (es) 2015-01-30
CA2871614C (en) 2021-08-31
KR102046435B1 (ko) 2019-11-19
SI2841575T1 (sl) 2019-11-29
MX2014013081A (es) 2015-01-12
CA2871614A1 (en) 2013-10-31
EA034689B1 (ru) 2020-03-06
HRP20191690T1 (hr) 2019-12-27
CO7280144A2 (es) 2015-05-29
CY1122557T1 (el) 2021-01-27
CN104395470A (zh) 2015-03-04
HUE046404T2 (hu) 2020-02-28
PE20142322A1 (es) 2015-01-25
WO2013163633A1 (en) 2013-10-31
EA201491977A1 (ru) 2015-04-30
EP2841575A1 (en) 2015-03-04
JP2015516985A (ja) 2015-06-18
CR20140497A (es) 2015-02-10
GEP201706737B (en) 2017-09-25
EP2841575A4 (en) 2016-06-15
SMT201900536T1 (it) 2019-11-13
US9000129B2 (en) 2015-04-07
SA113340502B1 (ar) 2015-09-17
AR090884A1 (es) 2014-12-10
EP2841575B1 (en) 2019-06-26
JP6472746B2 (ja) 2019-02-20
PH12014502399A1 (en) 2014-12-22
DOP2014000242A (es) 2014-11-30
RS59370B1 (sr) 2019-11-29
TN2014000454A1 (en) 2016-03-30
DK2841575T3 (da) 2019-09-23
ZA201407723B (en) 2019-01-30
JP2017131245A (ja) 2017-08-03
MA37569B1 (fr) 2020-08-31
NZ701601A (en) 2016-09-30
ECSP14028523A (es) 2015-09-30
AU2013251312A1 (en) 2014-10-30
PH12014502399B1 (en) 2022-04-22
PT2841575T (pt) 2019-10-11
LT2841575T (lt) 2019-10-10
MX362020B (es) 2019-01-04
TWI631137B (zh) 2018-08-01
AU2013251312B2 (en) 2018-03-22
US20160130344A1 (en) 2016-05-12
KR20150004882A (ko) 2015-01-13
UA117910C2 (uk) 2018-10-25
IL235307B (en) 2019-07-31
IL235307A0 (en) 2014-12-31
HK1208049A1 (en) 2016-02-19
SG11201406855TA (en) 2014-11-27
JP6517267B2 (ja) 2019-05-22

Similar Documents

Publication Publication Date Title
CN104395470B (zh) 抗‑gcc抗体分子和其用于测试对gcc标靶治疗的易感性的用途
US9662405B2 (en) Method of treating cancer by administering chimeric antigen receptor comprising anti-GCC antibody
US10941211B2 (en) Anti-GCC antibody molecules and related compositions and methods
HK1208049B (en) Anti-gcc antibody molecules and use of same to test for susceptibility to gcc-targeted therapy
BR112014026742B1 (pt) Moléculas de anticorpo anti-gcc, sequências ácido nucleico, vetor, método de produção uma molécula de anticorpo e usos de uma molécula de anticorpo anti-gcc, kit e mistura de reação
HK1173961B (en) Anti-gcc antibody molecules and related compositions and methods
HK1173961A (en) Anti-gcc antibody molecules and related compositions and methods

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20211026

Address after: Osaka, Japan

Patentee after: TAKEDA PHARMACEUTICAL Co.,Ltd.

Address before: Massachusetts, USA

Patentee before: MILLENNIUM PHARMACEUTICALS, Inc.